Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Santen

    - PMLiVE

    J&J’s Darzalex recommended by CHMP to treat smouldering multiple myeloma

    If approved, Darzalex would be the first therapy approved in the EU for SMM

    - PMLiVE

    Organon/Henlius announce EMA validation for Perjeta biosimilar HLX11

    The reference medicine holds approvals for multiple HER2-positive breast cancer indications

    - PMLiVE

    Rare diseases: Novartis’ Fabhalta recommended by CHMP for C3 glomerulopathy

    Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year

    EU flag

    Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa

    There is currently only one treatment authorised for the ultra-rare genetic blistering disease

    EU flag

    CHMP recommends Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years

    Approximately 480,000 cases of the mosquito-borne viral disease were reported globally in 2024

    - PMLiVE

    Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis

    The rare liver disease affects approximately 15 per 100,000 people in Europe

    - PMLiVE

    GSK’s Jemperli receives positive CHMP opinion for expanded endometrial cancer use

    Approximately 121,000 people are diagnosed with primary advanced or recurrent endometrial cancer each year in Europe

    - PMLiVE

    MHRA urges companies to prepare for Windsor Framework for medicines

    The new UK-wide arrangements for medicines will come into effect on 1 January 2025

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug lecanemab receives CHMP recommendation

    The neurodegenerative disorder affects an estimated 6.9 million people in Europe

    - PMLiVE

    Novartis’ Kisqali receives CHMP recommendation for early breast cancer patients

    Approximately 70% of all breast cancer patients have HR-positive/HER2-negative disease

    - PMLiVE

    Novo Nordisk’s Alhemo recommended by CHMP for haemophilia A and B

    The rare bleeding disorder affects approximately 1,125,000 people globally

    - PMLiVE

    Sanofi/Regeneron’s Dupixent approved by EMA for uncontrolled COPD in adults

    Approximately 220,000 COPD patients in the EU could be eligible for Dupixent treatment

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links